Tempus reported preliminary fourth-quarter revenue of approximately $367 million, an 83% year-over-year increase driven by diagnostics volume growth in oncology and hereditary disease testing. The company attributed most gains to testing revenue and reported expanding data and applications sales; Tempus also disclosed more than $1.1 billion in total contract value from over 70 customers. The results, provided ahead of a JP Morgan presentation, signal market demand for integrated sequencing and data services. Tempus’s rise reflects continued payer and provider interest in outsourced molecular testing and commercial-stage data licensing.